Background: Despite the demonstrated efficacy and safety of biosimilar filgrastim-aafi (Nivestim™), few studies have compared its use in real-life clinical practice to the originator filgrastim (Neupogen™).
Objectives: This study aimed to compare the effectiveness and safety of filgrastim and filgrastim-aafi for the primary prophylaxis of chemotherapy induced-febrile neutropenia in the real-life setting.
Patients And Methods: A retrospective cohort study included all adult cancer patients at the King Hussein Cancer Centre requiring primary prophylaxis for chemotherapy-induced febrile neutropenia between 2014 and 2016.
Objectives: Admission to the Intensive Care Unit (ICU) is considered a distress journey with an increased demand and cost for informal caregiving. This study aimed to generate utility values through assessing the quality of life (QoL) of family caregivers using the EQ-5D-3L measure before and after ICU admission of their family members.
Methods: A 1-year prospective cohort study (January 2017 to February 2018) was conducted at a comprehensive cancer center in Jordan.
Int J Technol Assess Health Care
April 2021
Objective: To describe the establishment of, and assess the implementation of, a hospital-based health technology assessment (HTA) program in a comprehensive cancer center in Jordan.
Methods: This is a cross-sectional assessment study of the HTA program from 2008 to 2018. We used an indicator-based assessment that included structural, process, and outcome indicators.
Introduction: Implementation of health technology assessment (HTA) is still in an early stage with some heterogeneity in the Middle East and North Africa (MENA). Our objective was to assess the current and future status of HTA implementation in the MENA region by focusing on regional commonalities.
Methods: Preparatory discussions for the first ISPOR conference in the MENA region indicated some potentially generalizable trends of HTA roadmaps.
Background And Objective: Cancer patients are more likely to experience adverse drug reactions (ADRs) than other patients, because of both the complexity of the treatment regimens and the severity of disease. The objectives of this study were to determine the knowledge, attitude, and practice of health-care providers toward pharmacovigilance and ADR reporting, barriers to ADR reporting, and the association between the demographics of health-care providers and their knowledge and attitude toward reporting.
Materials And Methods: A cross-sectional survey was conducted at the King Hussein Cancer Center.
© LitMetric 2025. All rights reserved.